PMCDx Democratizes Precision Medicine, Setting a New Standard for Advanced Genomic Care

Personalized Medicine Care Diagnostics (PMCDx), a Maryland-based biotech startup, has been recognized for its leadership in integrating advanced genomics into routine clinical practice. Founded in 2020 by Dr. Sherry Dadgar, the company operates a CLIA-certified and CAP-accredited laboratory offering comprehensive services including Whole Exome and Whole Genome Sequencing. By focusing on interoperable data and accessible diagnostic tools like the RenaDx renal panel, PMCDx aims to bridge the gap between complex molecular data and actionable clinical insights for healthcare providers and patients alike.

PMCDx, headquartered in Germantown, Maryland, has established itself as a significant player in the precision medicine market by offering a wide array of high-complexity genetic and molecular tests. The company’s portfolio includes over 400 clinical genetic panels covering both pediatric and adult conditions, ranging from rare disorders to common hereditary diseases. Notably, PMCDx is among the first laboratories in the United States to offer Whole Exome Sequencing (WES) as a reflex test for adult rare-disease cases without additional costs to patients or physicians, a move designed to eliminate financial barriers to comprehensive genomic analysis and improve diagnostic yields.

A core focus of the company’s innovation is nephrogenomics, where it competes as one of only two providers—alongside Natera—offering comprehensive genetic testing for kidney disease. Its RenaDx platform utilizes a 449-gene renal panel with enhanced sequencing technology, while the RenaXome reflex test leverages WES to assist in diagnosing complex kidney conditions. Beyond renal care, PMCDx provides pharmacogenetics (PGx) testing to tailor medication selection to a patient’s genetic profile and molecular infectious disease testing that includes smart reporting algorithms for antibiotic-resistance patterns, which is increasingly critical for hospital and nursing-home care.

Since its inception in 2020, PMCDx has grown to over 30 employees and achieved profitability while operating within the Pinkney Innovation Complex for Science and Technology (PIC MC). Led by founder Dr. Sherry Dadgar, PhD, FACMG, the organization emphasizes the integration of clinical genetics and informatics to ensure genomic data is interoperable with electronic medical systems. This integrated model, which combines genomics, PGx, and infectious disease diagnostics, is intended to scale precision medicine for community physicians and health systems by translating complex molecular information into clear, actionable treatment paths that were previously difficult to access outside of specialized academic centers.